Zytiga for Prostate Cancer – Details


( Last Updated : May 3, 2019)
Generic Name:
Abiraterone
Project Status:
Withdrawn
Manufacturer:
Janssen Inc.
Brand Name:
Zytiga
Project Line:
Reimbursement Review
Project Number:
PC0166-000
NOC Date:

Details


Strength:
250 mg & 500 mg
Tumour Type:
Genitourinary
Indications:
Prostate Cancer
Funding Request:
Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy
Review Status:
Withdrawn
Sponsor:
BC Cancer Agency
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Clarification:
BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.